MedTrace Logo

Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects

NCT05905484 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2023-06-15

No results posted yet for this study

Summary

This study will assess the effects of Bemnifosbuvir on cardiac repolarization in healthy Adult Subjects

Conditions

  • Healthy Volunteer Study

Interventions

DRUG

Bemnifosbuvir (BEM)

A single dose of BEM will be administered.

DRUG

Placebo

A single dose of matching placebo will be administered.

DRUG

Moxifloxacin

A single dose of Moxifloxacin will be administered.

Sponsors & Collaborators

  • Atea Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-04-25
Primary Completion
2023-05-31
Completion
2023-05-31
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05905484 on ClinicalTrials.gov